These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 24247886)

  • 1. Combination of BK channel opener and Kv4 channel inhibitor for treatment of cerebellar ataxia in mutant med mice.
    Abbasi S; Abbasi A; Sarbaz Y
    J Neuropsychiatry Clin Neurosci; 2013; 25(4):E41. PubMed ID: 24247886
    [No Abstract]   [Full Text] [Related]  

  • 2. Introducing treatment strategy for cerebellar ataxia in mutant med mice: combination of acetazolamide and 4-aminopyridine.
    Abbasi S; Abbasi A; Sarbaz Y
    Comput Methods Programs Biomed; 2014 Feb; 113(2):697-704. PubMed ID: 24326337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation.
    Schniepp R; Wuehr M; Ackl N; Danek A; Brandt T; Strupp M; Jahn K
    J Neurol; 2011 Sep; 258(9):1708-11. PubMed ID: 21431381
    [No Abstract]   [Full Text] [Related]  

  • 4. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.
    Giordano I; Bogdanow M; Jacobi H; Jahn K; Minnerop M; Schoels L; Synofzik M; Teufel J; Klockgether T
    J Neurol; 2013 Aug; 260(8):2175-6. PubMed ID: 23824358
    [No Abstract]   [Full Text] [Related]  

  • 5. Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia--a comment.
    Strupp M; Kalla R; Freilinger T; Dichgans M; Brandt T
    Brain; 2005 Jun; 128(Pt 6):E32; author reply E33. PubMed ID: 15900025
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
    Strupp M; Kalla R; Dichgans M; Freilinger T; Glasauer S; Brandt T
    Neurology; 2004 May; 62(9):1623-5. PubMed ID: 15136697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
    Alviña K; Khodakhah K
    J Neurosci; 2010 May; 30(21):7258-68. PubMed ID: 20505092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Episodic ataxia type 2.
    Strupp M; Zwergal A; Brandt T
    Neurotherapeutics; 2007 Apr; 4(2):267-73. PubMed ID: 17395137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel Activators of Large-Conductance Calcium-Activated Potassium Channels for the Treatment of Cerebellar Ataxia.
    Srinivasan SR; Huang H; Chang WC; Nasburg JA; Nguyen HM; Strassmaier T; Wulff H; Shakkottai VG
    Mol Pharmacol; 2022 Jul; 102(1):438-449. PubMed ID: 35489717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the pharmacotherapy of cerebellar and central vestibular disorders.
    Kalla R; Teufel J; Feil K; Muth C; Strupp M
    J Neurol; 2016 Apr; 263 Suppl 1():S24-9. PubMed ID: 27083881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
    Sprenger A; Rambold H; Sander T; Marti S; Weber K; Straumann D; Helmchen C
    Neurology; 2006 Sep; 67(5):905-7. PubMed ID: 16966567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered expression of voltage-gated potassium channel 4.2 and voltage-gated potassium channel 4-interacting protein, and changes in intracellular calcium levels following lithium-pilocarpine-induced status epilepticus.
    Su T; Cong WD; Long YS; Luo AH; Sun WW; Deng WY; Liao WP
    Neuroscience; 2008 Dec; 157(3):566-76. PubMed ID: 18930118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.
    Feil K; Bremova T; Muth C; Schniepp R; Teufel J; Strupp M
    Cerebellum; 2016 Feb; 15(1):38-42. PubMed ID: 26519380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-conductance, calcium-activated potassium channels: structural and functional implications.
    Ghatta S; Nimmagadda D; Xu X; O'Rourke ST
    Pharmacol Ther; 2006 Apr; 110(1):103-16. PubMed ID: 16356551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalfampridine (Ampyra) for MS.
    Med Lett Drugs Ther; 2010 Sep; 52(1347):73-4. PubMed ID: 20847716
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fampridine and multiple sclerosis].
    Mathiesen HK; Sørensen PS
    Ugeskr Laeger; 2014 Jan; 176(3A):V06130416. PubMed ID: 25347174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voltage-gated potassium currents in rat vas deferens smooth muscle cells.
    Harhun MI; Jurkiewicz A; Jurkiewicz NH; Kryshtal DO; Shuba MF; Vladimirova IA
    Pflugers Arch; 2003 Jun; 446(3):380-6. PubMed ID: 12684789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxyhemoglobin-induced suppression of voltage-dependent K+ channels in cerebral arteries by enhanced tyrosine kinase activity.
    Ishiguro M; Morielli AD; Zvarova K; Tranmer BI; Penar PL; Wellman GC
    Circ Res; 2006 Nov; 99(11):1252-60. PubMed ID: 17068294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
    Judge SI; Bever CT
    Pharmacol Ther; 2006 Jul; 111(1):224-59. PubMed ID: 16472864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report.
    Löhle M; Schrempf W; Wolz M; Reichmann H; Storch A
    Mov Disord; 2008 Jul; 23(9):1314-6. PubMed ID: 18442126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.